<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Traumatology and Orthopedics of Russia</journal-id><journal-title-group><journal-title xml:lang="en">Traumatology and Orthopedics of Russia</journal-title><trans-title-group xml:lang="ru"><trans-title>Травматология и ортопедия России</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2311-2905</issn><issn publication-format="electronic">2542-0933</issn><publisher><publisher-name xml:lang="en">Vreden National Medical Research Center of Traumatology and Orthopedics</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">944</article-id><article-id pub-id-type="doi">10.21823/2311-2905-2018-24-1-144-154</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="zh"><subject>Reviews</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">ACETYLSALICYLIC ACID FOR THROMBOEMBOLISM PROPHYLAXIS. DOES IT REALLY WORK OR IT’S A GRIMACE OF THE EVIDENCE-BASED MEDICINE?</article-title><trans-title-group xml:lang="ru"><trans-title>АЦЕТИЛСАЛИЦИЛОВАЯ КИСЛОТА ДЛЯ ПРОФИЛАКТИКИ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ. РЕАЛЬНО РАБОТАЕТ ИЛИ ГРИМАСА ДОКАЗАТЕЛЬНОЙ МЕДИЦИНЫ?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sereda</surname><given-names>A. P.</given-names></name><name xml:lang="ru"><surname>Середа</surname><given-names>А. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med), Deputy Head</p><p>30, Volokolamskoye shosse, 23182, Moscow</p></bio><bio xml:lang="ru"><p>д-р мед. наук, заместитель руководителя </p><p>Волоколамское шоссе, д. 30, стр. 1, 23182, Москва</p></bio><email>drsereda@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Federal Medical Biological Agency</institution></aff><aff><institution xml:lang="ru">Федеральное медико-биологическое агентство России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-04-16" publication-format="electronic"><day>16</day><month>04</month><year>2018</year></pub-date><volume>24</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>144</fpage><lpage>154</lpage><history><date date-type="received" iso-8601-date="2018-04-15"><day>15</day><month>04</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2018-04-15"><day>15</day><month>04</month><year>2018</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://journal.rniito.org/jour/article/view/944">https://journal.rniito.org/jour/article/view/944</self-uri><abstract xml:lang="en"><p>Acetylsalicylic acid administration for pharmaceutical prophylaxis of thromboembolic complications is a highly controversial and debatable issue. Debates continue, and, in particularly, opposite views of ACCP recommendations (8th and 9th revisions), Russian clinical recommendations and AAOS guideline were discussed during the Vreden’s Readings conference in 2017 and motivated the authors to compile the present analytical review. The authors attempted to explain initial ban for use and later on sudden advisable use of acetylsalicylic acid for thromboembolism prophylaxis. There can be no unique answer to such a problem due to ambiguity of current state of evidence-based medicine and current system for defining the clinical guidelines.</p></abstract><trans-abstract xml:lang="ru"><p>Использование ацетилсалициловой кислоты для фармакологической профилактики тромбоэмболических осложнений — весьма спорный и дискутабельный вопрос. Не прекращающиеся дискуссии, в частности, на последних «Вреденовских чтениях» в 2017 г. о противоречиях в рекомендациях American College of Chest Physicians восьмой и девятой редакций, Российских клинических рекомендаций и гайдлайна AAOS побудили написать этот аналитический обзор. Мы попытались объяснить, почему сначала ацетилсалициловая кислота запрещалась, а потом вдруг стала разрешена для профилактики тромбоэмболических осложнений. Ответ на этот вопрос не может быть однозначным, поскольку неоднозначна сама современная система доказательной медицины и формулирования клинических рекомендаций.</p></trans-abstract><kwd-group xml:lang="en"><kwd>acetylsalicylic acid</kwd><kwd>evidence-based medicine</kwd><kwd>clinical guideline</kwd><kwd>thromboembolic complications</kwd><kwd>pulmonary embolism</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ацетилсалициловая кислота</kwd><kwd>доказательная медицина</kwd><kwd>тромбоэмболические осложнения</kwd><kwd>тромбоэмболия легочной артерии</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. Hill J., Treasure T.; Guideline Development Group. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital: summary of the NICE guideline. Heart. 2010;96(11):879-882. doi: 10.1136/hrt.2010.198275.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. Scottish Intercollegiate Network Guidelines (SIGN) Guideline no. 62: Prophylaxis of venous thromboembolism. Available at: http://www.sign.ac.uk/ guidelines/fulltext/62/index.html. Accessed on 05/10/10</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3. Nicolaides A.N., Breddin H.K., Fareed J., Goldhaber S., Haas S., Hull R. et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol. 2001;20(1):1-37.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4. National Health and Medical Research Council. Clinical practice guideline for the prevention of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to Australian hospitals. Melbourne: National Health and Medical Research Council; 2009. https://www.nhmrc.gov.au/_files_nhmrc/ file/publications/cp115_guideline_prevention_venous_ thromboembolism_160722_rescinded.pdf</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5. Falck-Ytter Y., Francis C.W., Johanson N.A., Curley C., Dahl O.E., Schulman S., Ortel T.L., Pauker S.G., Colwell C.W. Jr. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines Chest. 2012;141 (2 Suppl):e278-e325. doi: 10.1378/chest.11-2404.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6. Geerts W.H., Pineo G.F., Heit J.A., Bergqvist D., Lassen M.R., Colwell C.W., Ray J.G. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126 (3 Suppl):338S-400S. DOI: 10.1378/chest.126.3_suppl.338S.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7. Geerts WH., Bergqvist D, Pineo G.F., Heit J.A., Samama C.M., Lassen M.R., Colwell C.W. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):381S-453S. doi: 10.1378/chest.08-0656.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8. American Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. Available at: http://www.aaos.org/ research/guidelines/VTE/VTE_full_guideline.pdf.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9. Российские клинические рекомендации «Профилактика венозных тромбоэмболических осложнений в травматологии и ортопедии». Травматология и ортопедия России. 2012; 1(приложение) :2-24. [Russian clinical guidelines «Prevention of venous thromboembolic complications in traumatology and orthopedics»]. Travmatologiya i ortopediya Rossii [Traumatology and orthopedics of russia]. 2012;1(suppl):1-24. (in Russian).</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10. Arcelus J.I., Villar J.M., Muñoz N. Should we follow the 9th ACCP guidelines for VTE prevention in surgical patients? Thromb Res. 2012;130(Suppl 1):S4-6. doi: 10.1016/j.thromres.2012.08.260.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., Schünemann H.J.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. doi: 10.1136/bmj.39489.470347.AD.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12. Guyatt G., Akl E.A., Hirsh J., Kearon C., Crowther M., Gutterman D., Lewis S.Z., Nathanson I., Jaeschke R., Schünemann H. The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med. 2010;152(11):738-741. doi: 10.7326/0003-4819-152-11-201006010-00254.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13. Haas S.B., Barrack R.L., Westrich G., Lachiewicz P.F. Venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2008;90(12):2764-2780.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14. Johanson N.A., Lachiewicz P.F., Lieberman J.R., Lotke P.A., Parvizi J., Pellegrini V., Stringer T.A,. Tornetta P. 3rd, Haralson R.H. 3rd, Watters W.C. 3rd. American academy of orthopaedic surgeons clinical practice guideline on. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Bone Joint Surg Am. 2009;91(7):1756- 7175. doi: 10.2106/JBJS.I.00511.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15. Guyatt G.H., Akl E.A., Crowther M., Schünemann H.J., Gutterman D.D., Lewis S.Z. Introduction to the ninth edition: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):48S-52S. doi: 10.1378/chest.11-2286.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355(9212): 1295-1302.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17. Alfaro M.J., Páramo J.A., Rocha E. Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: a comparative study of aspirin and heparin-dihydroergotamine. Thromb Haemost. 1986;56(1):53-56 .</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18. Dechavanne M., Ville D., Viala J.J. , Kher A., Faivre J., Pousset M.B., Dejour H. Controlled trial of platelet anti-aggregating agents and subcutaneous heparin in prevention of postoperative deep vein thrombosis in high risk patients. Haemostasis. 1975;4(2):94-100.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19. Harris W.H., Salzman E.W., Athanasoulis C.A., Waltman A.C., DeSanctis R.W. Aspirin prophylaxis of venous throm-boembolism after total hip replacement. N Engl J Med. 1977;297(23):1246-1249.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20. McBride J.A., Turpie A.G., Kraus V., Hilz C. Proceedings: failure of aspirin and dipyridamole to influence the incidence of leg scan detected venous thrombosis after elective hip surgery. Thromb Diath Haemorrh. 1975;34(2):564 .</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21. Sautter R.D., Koch E.L., Myers W.O., Ray J.R. 3rd, Mazza J.J., Larson D.E. et al. Aspirin-sulfinpyrazone in prophylaxis of deep venous thrombosis in total hip replacement. JAMA. 1983;250(19):2649-2654 .</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22. McKenna R., Galante J., Bachmann F., Wallace D.L., Kaushal P.S., Meredith P. Prevention of venous thromboembolism after total knee replacement by highdose aspirin or intermittent calf and thigh compression. BMJ. 1980;280(6213):514-517 .</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23. Encke A., Stock C., Dumke H.O. Double-blind study for the prevention of postoperative thrombosis. Chirurg. 1976; 4 (12):670-673. (in German]).</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24. Morris G.K., Mitchell J.R. Preventing venous thromboembo-lism in elderly patients with hip fractures: studies of low-dose heparin, dipyridamole, aspirin, and flurbiprofen . BMJ. 1977;1(6060):535-537.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25. Powers P.J., Gent M., Jay R.M., Julian D.H., Turpie A.G., Levine M., Hirsh J. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med. 1989; 149(4):771-774.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>26. Snook G.A., Chrisman O.D., Wilson T.C. Thromboembolism after surgical treatment of hip fractures. Clin Orthop Relat Res. 1981;(155):21-24 .</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>27. Wood E.H., Prentice C.R., McGrouther D.A., Sinclair J., McNicol G.P. Trial of aspirin and RA 233 in prevention of post-operative deep vein thrombosis. Thromb Diath Haemorrh. 1973;30(1):18-24.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>28. Zekert F., Kohn P., Vormittag E., Poigenfürst J., Thien M. [Prevention of thromboembolism using acetylsalicylic acid in the surgery of hip-joint proximal fractures]. Monatsschr Unfallheilkd Versicher Versorg Verkehrsmed.1974;77(3):97-110. (in German).</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>29. Westrich G.H., Bottner F., Windsor R.E., Laskin R.S., Haas S.B., Sculco T.P. VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. J Arthroplasty. 2006;21(6 suppl 2):139-143.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>30. Graor R.A.S.J., Lotke P.A., Davidson B.L. RD heparin (ardeparin sodium) vs. aspirin to prevent deep venous thrombosis after hip or knee replacement surgery [abstract] . Chest. 1992 ; 102 (suppl): 118S.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>31. National Institute for Health and Clinical Excellence. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients under-going surgery. NICE clinical guideline No. 46:1-160. Available at: http://www.nice.org.uk/ CG046. Accessed March 31, 2008.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>32. Antiplatelet Trialists’ Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994;308(6923):235-246.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>33. Cohen A.T., Skinner J.A., Kakkar V.V. Antiplatelet treatment for thromboprophylaxis: a step forward or backwards? BMJ. 1994;309:1213-1215.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>34. Lieberman JR., Heckmann N. Venous thromboembolism prophylaxis in total hip arthroplasty and total knee arthroplasty patients: from guidelines to practice. J Am Acad Orthop Surg. 2017;25(12):789-798. doi: 10.5435/JAAOS-D-15-00760.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>35. Westrich G.H., Sculco T.P. Prophylaxis against deep venous thrombosis after total knee arthroplasty: pneumatic planter compression and aspirin compared with aspirin alone. J Bone Joint Surg Am. 1996;78(6):826-834.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>36. Gent M., Hirsh .J, Ginsberg J.S., Powers P.J., Levine M.N., Geerts W.H., Jay R.M., Leclerc J., Neemeh J.A., Turpie A.G. Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation. 1996;93(1):80-84.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>37. Bergqvis D., Arcelus J.I., Felicissimo P.; ETHOS investigators. Evaluation of the duration of thromboembolic prophylaxis after high-risk orthopedic surgery: The ETHOS observational study. Thromb Haemost. 2012;107(2):270-279. doi: 10.1160/TH11-07-0463.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>38. Cohen A.T., Tapson V.F., Bergmann J.F., Goldhaber S.Z., Kakkar A.J., Deslandes B., Huang W., Zayaruzny M., Emery L., Anderson F.A. Jr; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610): 387-394. doi: 10.1016/S0140-6736(08)60202-0.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>39. Bozic K.J., Vail T.P., Pekow P.S., Maselli J.H., Lindenauer P.K., Auerbach A.D. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty. 2010;25(7):1053-1060. doi: 10.1016/j.arth.2009.06.021.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>40. Khatod M., Inacio M.C.S., Bini S.A., Paxton E.W. Pulmonary embolism prophylaxis in more than 30, 000 total knee arthroplasty patients: is there a best choice? J Arthroplasty. 2012;27(2):167-172. doi: 10.1016/j.arth.2011.04.006.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>41. Lotke P.A., Lonner J.H. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop Relat Res. 2006;452:175-180. DOI: 10.1097/01.blo.0000238822.78895.95</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>42. A prospective comparison of warfarin to aspirin for thromboprophylaxis in total hip and total knee arthroplasty. J Arthroplasty. 2012;27(1):1-9.e2. DOI: 10.1016/j.arth.2011.03.032.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>43. Vulcano E., Gesell M., Esposito A., Ma Y., Memtsoudis S.G., Gonzalez Della Valle A. Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol. Int Orthop. 2012;36(10):1995-2002. doi: 10.1007/s00264-012-1588-4.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>44. Anderson D.R., Dunbar M.J., Bohm E.R., Belzile E., Kahn S.R., Zukor D., Fisher W., Gofton W., Gross P., Pelet S., Crowther M., MacDonald S., Kim P., Pleasance S., Davis N., Andreou P., Wells P., Kovacs M., Rodger M.A., Ramsay T., Carrier M., Vendittoli P.A. Aspirin versus low-molecularweight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013;158(11):800-806. doi: 10.7326/0003-4819-158-11-201306040-00004.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>45. Aquilina A.L., Brunton L.R., Whitehouse M.R., Sullivan N., Blom A.W. Direct thrombin inhibitor (DTI) vs. aspirin in primary total hip and knee replacement using wound ooze as the primary outcome measure. A prospective cohort study. Hip Int. 2012;22(1):22-27. doi: 10.5301/HIP.2012.9058.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>46. Intermountain Joint Replacement Center Writing Committee. A prospective comparison of warfarin to aspirin for thromboprophylaxis in total hip and total knee arthroplasty. J Arthroplasty. 2012 Jan;27(1):1-9.e2. Epub 2011 May 31. doi: 10.1016/j.arth.2011.03.032.</mixed-citation></ref></ref-list></back></article>
